Stocks News

What AstraZeneca gains from acquiring Fusion Pharmaceuticals (AZN)

Chessboard with chess pieces and wooden blocks with the words Mergers and Acquisitions

sorry

AstraZeneca (NASDAQ:AZN) announced that it would take over. Convergence Pharmaceutical (NASDAQ:FUSN) of $21 per share, or approximately $2 billion, plus contingent value rights (“CVR”) of $3 per share payable upon achievement of certain regulatory milestones, bringing the total potential value

Related Articles

Back to top button